Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”

Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”. Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. Science, 340(6135):924--924, May, 2013.

Paper doi abstract bibtex

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer’s disease (AD) that treatment of APP/PS1ΔE9 mice with bexarotene decreased Aβ pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1ΔE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Aβ, but not the effects on amyloid deposition.

@article{fitz_comment_2013,
	title = {Comment on “{ApoE}-{Directed} {Therapeutics} {Rapidly} {Clear} β-{Amyloid} and {Reverse} {Deficits} in {AD} {Mouse} {Models}”},
	volume = {340},
	copyright = {Copyright © 2013, American Association for the Advancement of Science},
	issn = {0036-8075, 1095-9203},
	url = {http://science.sciencemag.org/content/340/6135/924.3},
	doi = {10.1126/science.1235809},
	abstract = {Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer’s disease (AD) that treatment of APP/PS1ΔE9 mice with bexarotene decreased Aβ pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1ΔE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Aβ, but not the effects on amyloid deposition.},
	language = {en},
	number = {6135},
	urldate = {2016-09-16TZ},
	journal = {Science},
	author = {Fitz, Nicholas F. and Cronican, Andrea A. and Lefterov, Iliya and Koldamova, Radosveta},
	month = may,
	year = {2013},
	pmid = {23704552},
	pages = {924--924}
}

Downloads: 0

{"_id":"u2QoDxRESBYkjK9at","bibbaseid":"fitz-cronican-lefterov-koldamova-commentonapoedirectedtherapeuticsrapidlyclearamyloidandreversedeficitsinadmousemodels-2013","downloads":0,"creationDate":"2016-10-20T23:18:54.563Z","title":"Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”","author_short":["Fitz, N. F.","Cronican, A. A.","Lefterov, I.","Koldamova, R."],"year":2013,"bibtype":"article","biburl":"https://api.zotero.org/users/904733/collections/QZ5K9B7C/items?key=cWrtxOIc37LVDhuHVL2gNrpN&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”","volume":"340","copyright":"Copyright © 2013, American Association for the Advancement of Science","issn":"0036-8075, 1095-9203","url":"http://science.sciencemag.org/content/340/6135/924.3","doi":"10.1126/science.1235809","abstract":"Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer’s disease (AD) that treatment of APP/PS1ΔE9 mice with bexarotene decreased Aβ pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1ΔE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Aβ, but not the effects on amyloid deposition.","language":"en","number":"6135","urldate":"2016-09-16TZ","journal":"Science","author":[{"propositions":[],"lastnames":["Fitz"],"firstnames":["Nicholas","F."],"suffixes":[]},{"propositions":[],"lastnames":["Cronican"],"firstnames":["Andrea","A."],"suffixes":[]},{"propositions":[],"lastnames":["Lefterov"],"firstnames":["Iliya"],"suffixes":[]},{"propositions":[],"lastnames":["Koldamova"],"firstnames":["Radosveta"],"suffixes":[]}],"month":"May","year":"2013","pmid":"23704552","pages":"924--924","bibtex":"@article{fitz_comment_2013,\n\ttitle = {Comment on “{ApoE}-{Directed} {Therapeutics} {Rapidly} {Clear} β-{Amyloid} and {Reverse} {Deficits} in {AD} {Mouse} {Models}”},\n\tvolume = {340},\n\tcopyright = {Copyright © 2013, American Association for the Advancement of Science},\n\tissn = {0036-8075, 1095-9203},\n\turl = {http://science.sciencemag.org/content/340/6135/924.3},\n\tdoi = {10.1126/science.1235809},\n\tabstract = {Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer’s disease (AD) that treatment of APP/PS1ΔE9 mice with bexarotene decreased Aβ pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1ΔE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Aβ, but not the effects on amyloid deposition.},\n\tlanguage = {en},\n\tnumber = {6135},\n\turldate = {2016-09-16TZ},\n\tjournal = {Science},\n\tauthor = {Fitz, Nicholas F. and Cronican, Andrea A. and Lefterov, Iliya and Koldamova, Radosveta},\n\tmonth = may,\n\tyear = {2013},\n\tpmid = {23704552},\n\tpages = {924--924}\n}\n\n","author_short":["Fitz, N. F.","Cronican, A. A.","Lefterov, I.","Koldamova, R."],"key":"fitz_comment_2013","id":"fitz_comment_2013","bibbaseid":"fitz-cronican-lefterov-koldamova-commentonapoedirectedtherapeuticsrapidlyclearamyloidandreversedeficitsinadmousemodels-2013","role":"author","urls":{"Paper":"http://science.sciencemag.org/content/340/6135/924.3"},"downloads":0},"search_terms":["comment","apoe","directed","therapeutics","rapidly","clear","amyloid","reverse","deficits","mouse","models","fitz","cronican","lefterov","koldamova"],"keywords":[],"authorIDs":[],"dataSources":["qF4FqjP6duD3xaQAi"]}